Vnitr Lek 2020, 66(4):214-224 | DOI: 10.36290/vnl.2020.064

Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia

Katarína Slezáková, Martin Mistrík, Angelika Bátorová
Klinika hematológie a transfuziológie LF UK, SZU a UN Bratislava, Slovenská republika

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia that is characterised by Philadelphia chromosome (Ph1 chromosome) and/or fusion gene BCR-ABL1 in bone marrow. Interpheron α and bone marrow transplantation used to be the main treatment modalities for patients with CML 20 years ago. Due to the introduction of imatinib mesylate since the year 2000 the outcome of CML patients has dramatically improved. The survival of both younger and elderly patients in the case of an optimal response has been prolonged and currently is close to survival of healthy population. Although, one third of patients does not respond well to first line imatinib and needs to change the treatment to second line tyrosine kinase inhibitors (TKI: bosutinib, dasatinib and nilotinib). Younger patients without cardiologic and metabolic disorders and those with poor risk profile score may have benefit from TKI of 2nd generation as a 1st line treatment option with the aim of reaching deeper molecular response and the chance of treatment free remission (TFR) in future. By older patients with severe comorbidities and in patients with good risk profile score imatinib as a 1st line treatment option can be used. For patients who are resistant simultaneously to 2nd generation TKI and for patients with mutation T315I ponatinib - TKI of 3rd generation can be used effectively. Intolerance and toxicity of TKI´s are the main barriers of effective CML treatment. TKI selection for each patient should be individual. Patient´s cooperation with medical team is crucial and inevitable in long time treatment process. The chance for TFR has become feasible for approximately 40-60 % CML patients in deep and durable molecular remission and represents a further important milestone in the management of CML patients.

Keywords: bosutinib, dasatinib, hematopoietic stem cell transplantation, chronic myeloid leukemia, imatinib, nilotinib, ponatinib, remission, tyrosine kinase inhibitors.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slezáková K, Mistrík M, Bátorová A. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia. Vnitr Lek. 2020;66(4):214-224. doi: 10.36290/vnl.2020.064.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. O'Brien S, Berman E, Moore JO et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Cancer Netw 2011; 9: (Suppl. 2): S1-S25. Go to original source... Go to PubMed...
    2. Hehlmann R, Hochhaus A, Baccarani M European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350. Go to original source... Go to PubMed...
    3. Bower H, Björkholm M, Dickman PW et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016; 34: 2851-2857. Go to original source... Go to PubMed...
    4. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good‑risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799. Go to original source...
    5. Žáčková D Tyrozinkinázové inhibitory v léčbě starších pacientů s chronickou myeloidní leukémií - editorial. Vnitř Lék 2015; 61: 760-761. Go to PubMed...
    6. Hochhaus A, Larson RA, Guilhot MD et al. Long‑Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376: 917-927. Go to original source... Go to PubMed...
    7. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic‑phase chronic myeloid leukkemia. N Engl J Med 2010; 362: 2260-2270. Go to original source... Go to PubMed...
    8. Hehlmann R, Lauseker M, Saußele S et al. Assesment of imatinib as first‑line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non‑CML determinants. Leukemia 2017; 31: 2398-2406. Go to original source... Go to PubMed...
    9. Kantarjian HM, Giles F, Bhalla K et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow‑up results. Blood 2011; 117: 1141-114. Go to original source... Go to PubMed...
    10. Klamová H, Žižková H, Burda P et al. Současné trendy v léčbě a diagnostice chronické myeloidní leukemie. Transfuze Hematol dnes 2017; 23: (Suppl. 1): S34-S46.
    11. Etienne G, Guilhot J, Rea D et al. Long‑Term Follow‑Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol 2017; 35: 298-305. Go to original source... Go to PubMed...
    12. Saussele S, Richter J, Gilhot J et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO‑SKI): a prespecified interim analysis of a prospective, multicentre, non‑randomised, trial. Lancet Oncol 2018; 19: 747-757. Go to original source... Go to PubMed...
    13. Réa D, Nicolini FE, Tulliez M et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G‑TKI study. Blood 2017; 129: 846-854. Go to original source... Go to PubMed...
    14. Baccarani M, Deininger MW, Rosti G et al. European LeukemiaNet Recommendations for the management of chronic myeloid leukemia 2013. Blood 2013; 122: 872-884. Go to original source... Go to PubMed...
    15. Alhuraiji A, Kantarjian H, Boddu P et al. Prognostic significance of additional chromozomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018; 93: 84-90. Go to original source... Go to PubMed...
    16. Radich JP, Deininger M, Abboud CN et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Vanc Netw 2018; 16: 1108-1135. Go to original source... Go to PubMed...
    17. Cohen MH, Williams G, Johnson G et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942.
    18. Guilhot J, Baccarani M, Clark RE et al. Definitions, methodological and statictical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European Leukemia Net. Blood 2012; 119: 5963-5971. Go to original source... Go to PubMed...
    19. Hehlman R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first‑line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692. Go to original source... Go to PubMed...
    20. Gratwohl A, Pfirrmann M, Zander A et al. Long‑term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016; 30: 562-569. Go to original source... Go to PubMed...
    21. Westin JR, Kurzrock R It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 2012; 11: 2549-2555. Go to original source... Go to PubMed...
    22. Mayer J, Klamová H, Žáčková D et al. Imatinib v první linii léčby nemocných s nově diagnotikovanou chronickou myeloidní leukemií v chronické fázi. Transfuze Hematol dnes 2008; 14: 150-158.
    23. Hughes T, White D Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology 2013; 2013: 168-175. Go to original source... Go to PubMed...
    24. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low‑dose cytarabine for newly diagnosed chronic‑phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004. Go to original source... Go to PubMed...
    25. Breccia M, Cannella L, Frustraci A et al. Pleural‑pericardial effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 2005; 74: 89-90. Go to original source... Go to PubMed...
    26. Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-1206. Go to original source... Go to PubMed...
    27. Shah NP, Kim DW, Kantarjian H et al. Potent, transient inhibition of BCR‑ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation‑free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95: 232-240. Go to original source... Go to PubMed...
    28. Cortes JE, Saglio G, Kantarjian HM et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment‑naïve chronic myeloid patients trial. J Clin Oncol 2016; 34: 2333-2340. Go to original source... Go to PubMed...
    29. Breccia M, Stagno F, Luciano L et al. Dasatinib first‑line: Multicentric Italian experience outside clinical trials. Leuk Res 2016; 40: 24-29. Go to original source... Go to PubMed...
    30. Shah NP, Rousselot P, Schiffer Ch et al. Dasatinib in imatinib‑resistant or intolerant chronic‑phase, chronic myeloid leukemia patients: 7-year follow‑up of study CA180-034. Am J Hematol 2016; 91: 869-874. Go to original source... Go to PubMed...
    31. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib verzus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259. Go to original source... Go to PubMed...
    32. Saglio G, Hochhaus A, Hughes TP et al. ENESTnd Update: nilotinib (NIL) vs imatinib(IM) in patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CML‑CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long‑term outcomes. Blood 2013; 122: abstract 92.
    33. Hughes TP, Saglio G, Kantarjian HM et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-1360. Go to original source... Go to PubMed...
    34. Hochhaus A, Saglio G, Larson RA et al. Nilotinib is associated with a reduced incidence of BCR‑ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121: 3703-3708. Go to original source... Go to PubMed...
    35. Castagnetti F, Breccia M, Gugliotta G et al. Nilotinib 300 mg twice daily: an academic single‑arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica 2016; 101: 1200-1207. Go to original source... Go to PubMed...
    36. Cortes JE, Kantarjian HM, Brümmendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome‑positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567-4576. Go to original source... Go to PubMed...
    37. Cortes JE, Gambacorti‑Passerini C, Deininger MW et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 2018; 36: 231-237. Go to original source... Go to PubMed...
    38. Cortes JE, Khoudry HJ, Kantarjian HM et al. Long‑term bosutinib for chronic phase chronic myeloid keukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol 2016; 91: 1206-1214. Go to original source... Go to PubMed...
    39. O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan‑BCR/ABL inhibitor for chronic myeloid leukemia, potently imhibits the T315I mutant and overcomes mutation‑based resistance. Cancer Cell 2009; 16: 401-412.Další literatura u autorkya na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    40. Cortes JE, Kim DW, Pinilla‑Ibarz J et al. Ponatinib efficacy and safety in Philadelphia chromosome‑positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 293-404. Go to original source... Go to PubMed...
    41. Amer MH Cancer‑associated thrombosis: clinical presentation and survival. Cancer Manag Res 2013; 5: 165-178. Go to original source... Go to PubMed...
    42. Breccia M, Abruzzese E, Castagnetti F et al. Ponatinib as second‑line treatment in chronic phase chronic myeloid leukemia patients in real‑life practice. Annals of Hematology 2018; 97: 1577-1580 Go to original source... Go to PubMed...
    43. Gutierrez VG, Deininger MW, Baer ME et al. The OPTIC study: A multicenter, Randomized, Phase 2 Trial to Evaluate Three Starting Doses of Ponatinib With Response‑Based Dose Reduction in Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to Prior Tyrosine Kinase Therapy. Clinical Lymphoma, Myeloma and Leukemia 2018; 18: (Suppl. 1): S228-S229. Go to original source...
    44. Marcolino MS, Boersma E, Clementino NC et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011; 22: 2073-2079. Go to original source... Go to PubMed...
    45. Cardama AQ, Han X, Kantarjian A et al. Dasatinib‑induced platelet dysfunction. Blood 2007; 110: 2941. Go to original source...
    46. Iurlo A, Galimberti S, Abruzzese E et al. Pleural effusion and molecular response in dasatinib‑treated chronic myeloid patients in a real‑life Italian multicenter series. Ann Hematol 2018; 97: 95-100. Go to original source... Go to PubMed...
    47. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137. Go to original source... Go to PubMed...
    48. Cortes JE, Kim DW, Pinilla‑Ibarz J et al. A phase 2 trial of ponatinib in Philadelphia chromosome‑positive leukemias. N Engl J Med 2013; 369: 1783-1796. Go to original source... Go to PubMed...
    49. Hochhaus A, Saglio G, Hughes TP et al. Long‑term benefits and risks of fronline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-1054. Go to original source... Go to PubMed...
    50. Racil Z, Koritakova E, Sacha T et al. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Am J Hematol 2018; 93: E342-E345. Go to original source... Go to PubMed...
    51. Voglova J, Muzik E, Faber E et al. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 2011; 58: 256-262. Go to original source... Go to PubMed...
    52. Gugliotta G, Castagnetti F, Breccia M et al. Incidence of second primary malignancies and related mortality in imatinib‑treated chronic myeloid leukemia patients. Haematologica 2017; 102: 1530-1536. Go to original source... Go to PubMed...
    53. Faber E, Divoká M, Skoumalová I et al. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long‑term low‑grade toxicity of treatment. Leuk Lymphoma 2016; 52: 370-375. Go to original source... Go to PubMed...
    54. Clark RE, Polydoros F, Apperley JF et al. De‑escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukemia with stable major molecular response (DESTINY): an interim analysis of a non‑randomised, phase 2 trial. Lancet Haematol 2017; 4: e310-e316. Go to original source... Go to PubMed...
    55. Hochhaus A, Saussele S, Rosti G et al. Chronic myeloid leukemia: ESMO Clinical Practic Guidelines for Diagnosis, treatment and follow up. Ann Oncol 2017; 28: (Suppl. 4): iv41-iv51. Go to original source... Go to PubMed...
    56. Hochhaus A, O'Brien SG, Guilhot F et al. Six‑year follow up of patients receiving imatinib for the first‑line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061. Go to original source... Go to PubMed...
    57. Rožmanová Š, Rohoň P, Divoká M et al. Hodnocení časné molekulární odpovědi po 3 měsících léčby imatinibem může u nemocných s chronickou myeloidní leukémií přispět k upřesnení odhadu prognózy - zkušenosti jednoho centra. Transfuze Hematol dnes 2014; 18: 66-71.
    58. Marin D, Ibrahim AR, Lucas C et al. Assesment of BCR‑ABL transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238. Go to original source... Go to PubMed...
    59. Holt JA, Woodliff HJ, Davis RE et al. Radiation and marrow infusion in leukemia. Observations on a patient with chronic granulocytic leukaemia treated with whole‑body radiation and infusion of isogenic marrow. Australas Radiol 1967; 11: 63-66. Go to original source... Go to PubMed...
    60. Craddock CF We do still transplant CML, don't we? ASH Education Book 2018; 1: 177-184. Go to original source... Go to PubMed...
    61. Rohrbacher M, Hasford J Epidemiology of chronic myeloid leukaemia. Best Pract Red Clin Haematol 2009; 22: 295-302. Go to original source... Go to PubMed...
    62. Hasford J, Baccarani M, Hoffmann V et al. Predicting complete cytogenetic response and subsequent progression‑free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686-692. Go to original source... Go to PubMed...
    63. Faber E, Mužík J, Koza V et al. Treatment of consecutive patients with chronic myeloid leukemia in the cooperating centers from the Czech Republic and the whole Slovakia after 2000 - a report from the CAMELIA Registry. Eur J Haematol 2011; 87: 157-168. Go to original source... Go to PubMed...
    64. Bělohlávková P, Voglová J, Radocha J et al. Má věk nemocných s chronickou myeloidní leukémií při léčbě imatinibem vliv na dosaženou léčebnou odpověď? Vnitř Lék 2015; 61: 785-791. Go to PubMed...
    65. Simonsson B, Hjorth‑Hansen H, Bjerrum OW et al. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets 2011; 12: 420-428. Go to original source... Go to PubMed...
    66. Regierer AC, Schulz CO, Kuehnhardt D et al. Interferon α - therapy for chronic myeloid leukaemia during pregnancy. Am J Haematol 2006; 81: 149-156. Go to original source... Go to PubMed...
    67. Kumagai T, Nakaseko C, Nishiwaki K et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci 2018; 109: 182-192. Go to original source... Go to PubMed...
    68. Hughes TP, Ross DM. Moving treatment‑free remission into mainstream clinical practice in CML. Blood 2016; 128: 17-23. Go to original source... Go to PubMed...
    69. Richter J, Soderlind S, Lubking A et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014; 32: 2821-2823. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.